Dynavax Gets DSMB Clearance To Continue Immunisations Of Two Phase 3 Heplisav Trials
Heplisav is a vaccine designed to protect against hepatitis B infection. The DSMB reviewed safety data from two ongoing multi-center Phase 3 trials evaluating Heplisav, one trial in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.